Plain-English translation of NCT07392372 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing a new medication called , which is a type of antibody designed to fight HIV. The study will first test safety in people without HIV, then move to people with HIV to see if the medication can help control the virus. Researchers want to understand how the body uses this medication and whether it reduces HIV levels.
Current HIV treatments work well for many people, but researchers are looking for new options that might work differently—like antibodies that can directly attack the virus. This trial will help determine if this new approach is safe enough and effective enough to pursue further in larger studies.
You likely qualify if…
You likely don't qualify if…
The study is divided into two parts. If you join the first part, you'll receive either the medication or a placebo by injection, then visit the clinic multiple times over about 9 months for blood tests and check-ups. If you join the second part (for people with HIV), you'll receive one dose of the medication and have frequent visits over 8 weeks to check your HIV levels with blood tests; then you'll start standard HIV treatment and continue follow-up visits for several more months. The entire study lasts about 10 months per person.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States
Germany